Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers

Hamam, Rimi; Hamam, Dana; Alsaleh, Khalid; Kassem, Moustapha; Zaher, Waleed; Alfayez, Musaad; Aldahmash, Abdullah; Alajez, Nehad M.

doi:10.1038/cddis.2017.440

Cited by 310 publications

(263 citation statements)

References 138 publications

Supporting

Mentioning

258

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies have been reported that miRNAs have regulatory functions in pathological processes, in particular in the development and progression of tumors . Hence, it is possible that many miRNAs could serve as biomarkers for the diagnosis of different types of cancer, including BC …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Aberrant expression of a five‐microRNA signature in breast carcinoma as a promising biomarker for diagnosis

Bitaraf

Babashah

Garshasbi

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most common malignancy among females with dismal quality of life in patients. It has been proven that epigenetic factors, especially microRNAs, are involved in breast carcinogenesis and progression. This study aimed to assess the expression and clinical performances of a five‐microRNA signature (miR‐127‐3p, miR‐133a‐3p, miR‐155‐5p, miR‐199b‐5p, and miR‐342‐5p) in breast cancer and adjacent normal tissues to identify a potential biomarker for BC and investigate the relationship between their expression and clinicopathological features of BC patients as well. Methods In this case‐control investigation, we recruited 50 pairs of tumor and matched non‐tumor surgical specimens from patients diagnosed with BC. Expression levels of miR‐127‐3p, miR‐133a‐3p, miR‐155‐5p, miR‐199b‐5p, and miR‐342‐5p were measured in BC and adjacent normal tissues by RT‐qPCR. Results We found that miR‐127‐3p, miR‐133a‐3p, miR‐199b‐5p, and miR‐342‐5p were significantly down‐regulated, while miR‐155‐5p was significantly up‐regulated in BC tumor tissues compared with the corresponding adjacent normal tissues. The decreased expression of miR‐127‐3p, miR‐133a‐3p, miR‐342‐5p, and up‐regulation of miR‐155‐5p showed a significant correlation with disease stage. We also found a significant down‐regulation of miR‐127‐3p, miR‐199b‐5p, and miR‐342‐5p compared in HER‐2‐negative patients. Our results indicated that miR‐155‐5p had a higher expression level in HER‐2‐positive patients. Receiver operating characteristic (ROC) curve analysis demonstrated that all these five microRNAs can serve as potential biomarkers to distinguish between tumor and non‐tumor breast tissue samples. Conclusions The present findings suggested that dysregulation of this five‐miRNA signature might be considered as a promising and functional biomarker for BC diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…miRNAs may play a crucial role a class of oncogenes or tumor suppressor genes in cancer . In BC, miRNA profiling has allowed for the identification of biomarker signatures associated with the diagnosis, staging, progression, and prognosis …”

Section: Introductionmentioning

confidence: 99%

Aberrant expression of a five‐microRNA signature in breast carcinoma as a promising biomarker for diagnosis

Bitaraf

Babashah

Garshasbi

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The predictive and prognostic value of miRNAs has been investigated in breast cancer . In a small study (n = 11), Kolacinska et al found higher expression of miR‐200b‐3p/miR‐190a along with lower expression of miR‐512‐5p in breast cancer tissue before chemotherapy correlated with a better pathologic response to NCT.…”

Section: Introductionmentioning

confidence: 99%

Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (miRNAs) have been indicated as predictive biomarkers in breast cancer. We aimed to explore the association of plasma miRNA dynamics with response to neoadjuvant chemotherapy (NCT) and disclose early markers for predicting sensitivity.MethodsOne hundred and nine patients with operable or locally advanced breast cancer, who participated in a prospective clinical trial and received NCT, were analyzed. Blood samples were collected before random assignment, after two cycles of chemotherapy (C2) and before surgery. Based on their clinical response, the patients were defined as chemo‐sensitive or insensitive. First, baseline and preoperative samples of selected cases from both groups were screened via TaqMan miRNA array for candidate miRNAs. Afterward all the biospecimens were tested for the candidate miRNAs (miR‐222, miR‐20a, miR‐451, miR‐9, miR‐34a, miR‐155, and miR‐145) by quantitative real‐time PCR. Finally, logistic regression model was utilized to determine the predictive value of baseline/C2 expression of these miRNAs.ResultsBased on the results of microRNA profiling, seven miRNAs were selected for further validation. In the HR+/HER2‐ cohort (n = 51) dynamics of three miRNAs, including miR‐222, miR‐20a, and miR‐451, were associated with chemo‐sensitivity. Importantly, across all the three subtypes we consistently identified chemo‐induced decrease in plasma miR‐34a in the insensitive patients. Finally, baseline miR‐222 overexpression (OR = 6.422, P = 0.049), C2 miR‐20a up‐regulation (OR = 0.144, P = 0.021) and C2 miR‐451 down‐regulation (OR = 8.213, P = 0.012) were predictive markers of response to NCT in HR+/HER2‐ breast cancer.ConclusionsWe described that dynamics of circulating miRNAs might help predict clinical response to NCT in breast cancer.

show abstract

“…[4][5][6] MiRNA is reported to be involved in diverse biological processes, such as cell proliferation, apoptosis and death. 7 Abnormal miRNA expression has been frequently observed in various human cancers, either as an oncogene or a tumor-suppressor.…”

mentioning

confidence: 99%

MiR-320d suppresses the progression of breast cancervialncRNA HNF1A-AS1 regulation and SOX4 inhibition

Shi

et al. 2018

RSC Adv.

View full text Add to dashboard Cite

MicroRNA-320d (miR-320d) is a novel cancer-related miRNA and functions as a tumor suppressor in human cancers. However, the expression pattern and function of miR-320d in breast cancer remain largely unknown. In the present study, we found that the expression level of miR-320d in breast cancer tissues and cells was significantly lower than in non-tumor tissues and MCF-10A cells. Decreased miR320d was associated with poor overall survival in patients with breast cancer. Overexpression of miR320d inhibited proliferation, migration, and invasion and promoted apoptosis of breast cancer cells. In addition, the long non-coding RNA, HNF1A antisense RNA 1 (HNF1A-AS1) was up-regulated in both breast cancer tissues and cell lines. HNF1A-AS1 suppressed the expression and function of miR-320d.Moreover, SRY-related HMG-box 4 (SOX4) was speculated and confirmed as a target of miR-320d. We also demonstrated that HNF1A-AS1 may function as a sponge competitive endogenous RNA for miR320d, and thus regulate the expression of SOX4. Taken together, our study has identified a novel signaling pathway through which miR-320d exerts its anti-carcinogenic roles and suggested that the HNF1A-AS1/miR-320d/SOX4 may be a potential target for the therapy of breast cancer.

show abstract

Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers

Cited by 310 publications

References 138 publications

Aberrant expression of a five‐microRNA signature in breast carcinoma as a promising biomarker for diagnosis

Aberrant expression of a five‐microRNA signature in breast carcinoma as a promising biomarker for diagnosis

Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer

MiR-320d suppresses the progression of breast cancervialncRNA HNF1A-AS1 regulation and SOX4 inhibition

Contact Info

Product

Resources

About